**Ozempic-Maker Sues Rival Eli Lilly Over False Advertising Claims**
Novo Nordisk, the Danish pharmaceutical company behind popular weight-loss medications Wegovy and Ozempic, has initiated legal proceedings against its competitor Eli Lilly, alleging false advertising. The lawsuit was filed in the United States on Tuesday and accuses Eli Lilly of misleading consumers regarding the effectiveness of its weight-loss drugs, Mounjaro and Zepbound.
According to Novo Nordisk, Eli Lilly's advertising campaigns create a false impression that its products outperform those of Novo Nordisk. The legal complaint highlights that Eli Lilly has compared the highest approved doses of its medications with lower doses of Novo Nordisk's offerings, while failing to mention the availability of newer, higher-dose options from Novo.
In its lawsuit, Novo Nordisk claims that Eli Lilly's advertising practices violate both federal and state laws concerning false advertising and unfair competition. The company argues that Eli Lilly's ads have selectively used outdated clinical studies to present a skewed comparison, thereby misleading potential consumers about the relative effectiveness of the drugs.
John F. Kuckelman, senior vice president and group general counsel for Novo Nordisk, emphasized the importance of accurate information in healthcare. "As new and more effective treatment options become available, people deserve accurate information that reflects the latest scientific evidence and helps them make informed care decisions," he stated. Kuckelman criticized Eli Lilly's advertising for relying on "ineffective, fine-print disclaimers" that do not adequately address the misleading nature of their campaigns.
Novo Nordisk is seeking a court order to compel Eli Lilly to cease its current advertising practices and to implement a "corrective advertising campaign" to clarify the information presented. If Eli Lilly does not voluntarily withdraw the disputed advertisements, Novo Nordisk plans to file a motion for a preliminary injunction to halt their distribution.
The lawsuit comes amid a competitive landscape in the weight-loss drug market, which is experiencing rapid growth, particularly in the United States. Analysts project that this market could exceed $100 billion by 2030, intensifying the rivalry between pharmaceutical companies like Novo Nordisk and Eli Lilly.
As of now, Eli Lilly has not publicly responded to the allegations made by Novo Nordisk. The outcome of this legal battle could have significant implications for both companies and the broader market for weight-loss medications.